Replies to post #2233 on InMed Pharmaceuticals Inc (INM)

[lesgetrich]

I just don't get the point of it as any serious company developing cannabinoids is not extracting from the plant. They're using biosynthesis. Maybe InMed has a better technology but there's no way of knowing if their PR compares it to plant extraction that nobody is doing.

Again you're making a dubious claim. Dozens of companies now produce CBD extracted from plant materials.

CBD Store

Supplying these brands alone with CBD would be a lucrative business. From their February 15 PR...

InMed Pharma CEO Discusses Company's Cannabinoid Biosynthesis -- CFN Media

The company's manufacturing technology will provide the compounds needed to research and commercialize their internal product candidates; however, it is estimated that the market for CBD alone, as an ingredient for mixing into other products, will surpass $2B by 2020. This manufacturing capability could very well be a huge stand-alone business opportunity for InMed.

As for having a better technology, Teewinot's process is synthetic. It involves chemical catalysts which can result in introduction of unwanted impurities and requires separate patents and processes for each of the 90+ synthetic compounds. It's a biocatalytic not purely biosynthetic process.

Patented biosynthesis produces 'authentic, standardized cannabinoids' for pharma

Our methods use the process of biosynthesis to react a starting material, cannabigerolic (CBGA) with either THCA synthase or CBDA synthase in order to produce pharmaceutically pure THCA, CBDA or CBCA

On the other hand, mCig claims to use genetically re-engineered bacteria. Once these bacteria are created they can presumably be reproduced and distributed with a royalty agreement or license.